CLEC16A

Across TCGA pan-cancer cohorts, CLEC16A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CLEC16A data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CLEC16A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CLEC16A expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where CLEC16A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.895	0.265	.001	29	view →
LUAD	DFS	Quartile	II,III,IV	0.800	0.994	.009	17	view →
CCRCC	DFS	Quartile	III,IV	0.310	0.693	.011	9	view →
UCEC	DFS	Quartile	All	0.925	0.728	.048	8	view →
LSCC	DFS	Quartile	II,III,IV	0.805	1.000	.019	4	view →
PDAC	OS	Tertile	III,IV	0.259	0.646	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CLEC16A–HNSC (DFS)

Open the HNSC breakdown →